SM7070P Osteoprotegerin antibody
see related secondary antibodiessee all 22 Osteoprotegerin products
0.1 mg / US$ 405
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Mouse anti Osteoprotegerin 98A1071
Synonyms
TNFRSF11B, OCIF, OPG, Osteoclastogenesis inhibitory factor, , Tumor necrosis factor receptor superfamily member 11B
Product Description
Mouse anti Osteoprotegerin 98A1071, Presentation: Purified. Product is tested for Immunofluorescence ( IF ), Paraffin Sections ( P ), Western blot / Immunoblot ( WB )
Properties
| Applications | Immunofluorescence ( IF ), Paraffin Sections ( P ), Western blot / Immunoblot ( WB ) |
| Reactivity | Human ( Hu ) |
| Presentation | Purified |
| Host | Mouse |
| Isotype | IgG1 |
| Clone | 98A1071 |
| Catalog Number | SM7070P |
| Swiss Prot. No. | O00300 |
| Quantity | 0.1 mg |
| Price | US$ 405 |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  SM7070P.pdf |
Datasheet Extract
| Concentration | 0.5 mg/ml |
| Background | Osteoprotegerin (OPG) is a secretory glycoprotein belonging to TNF receptor (TNFR) superfamily (1). As the name implies, it protects bone. Unlike other TNFRs it lacks a transmembrane domain and lacks any apparent cell associated signals. OPG consists of 401 amino acid with molecular mass of approximately 55 kD as a monomer and 110 kD as a disulfide-linked dimer. High levels of OPG mRNA has been detected in lung, heart, kidney, and placenta1. Recombinant OPG blocks osteoclastogenesis in vitro and increases bone density in vivo. Targeted deletion of OPG in mice results in severe early-onset of osteoporosity. These mice also exhibit increase in vascular calcification in the aorta and renal arteries suggesting that it may also play a role in degenerative arterial disease. |
| Immunogen | A peptide corresponding to the amino acids (aa) 20-37 of human OPG was used to immunize mice. Swiss Num.: O00300 AA Sequence: TQETFPPKYLHYDEETSH |
| Applications | Immunofluorescence/Immunocytochemistry: please see product citation #1 for details.
Immunohistochemistry on paraffin embedded sections: Product citation #9. Western Blot: 1 ug/ml. Recommended positive control: Daudi. |
| Specificity | The antibody recognizes Osteoprotegerin. Species: Human. |
| Add. Information | The specificity was tested on recombinant OPG by western blot analysis. |
| Storage | Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing. Shelf life: one year from despatch. |
| References | Product Citations
1. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Therese Standal, Carina Seidel, Vind Hjertner, Torben Plesner, Ralph D. Sanderson, Anders Waage, Magne Borset, and Anders Sundan. Blood,100: 3002-3007 (2002) (IHC). 2. Functional expression of receptor activator of nuclear factor B in Hodgkin disease cell lines. Paolo Fiumara, Virginia Snell, Yang Li, Asok Mukhopadhyay, Mamoun Younes, Ann Marie Gillenwater, Fernando Cabanillas, Bharat B. Aggarwal, and Anas Younes. Blood, 98: 2784-2790 (2001). 3. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Roger N. Pearse, Emilia M. Sordillo, Shmuel Yaccoby, Brian R. Wong, Deng F. Liau, Neville Colman, Joseph Michaeli, Joshua Epstein, and Yongwon Choi. PNAS, 98: 11581-11586 (2001). 4. 17 beta-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor. Mieko Saika, Daisuke Inoue, Shinsuke Kido, and Toshio Matsumoto. Endocrinology, 142: 2205-2212 (2001). References: 5. The Osteoprotegerin/Receptor Activator of Nuclear Factor kB/Receptor Activator of Nuclear Factor kB Ligand System in Cartilage. Hajime Komuro, Tsaiwei Olee, Klaus Kuhn, Jacqueline Quach, Diana C. Brinson, Alex Shikhman, Jean Valbracht, Lilo Creighto-Achermann, and Martin Lotz. ARTHRITIS & RHEUMATISM Vol. 44, No. 12, 2768-2776 (2001). (IHC on paraffin slides) 6. Osteoprotegerin in Human Milk: A Potential Role in the Regulation of Bone Metabolism and Immune Development. Karine Vidal, Peter van Den Boek, Florence Lorget, and Anne Donnet-Hughes. Pediatr. Res., Apr 2004. 7. Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis. Jonathan Golledge, Moira McCann, Simone Mangan, Alfred Lam, and Mirko Karan. Stroke, 35: 1636-1641 (2004). 8. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Karine Vidal, Patrick Serrant, Brigitte Schlosser, Peter van den Broek, Florence Lorget, and Anne Donne-Hughes. Am J Physiol Gastrointest Liver Physiol, 287: 83-844 (2004). 9. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. A R Moschen, A Kaser, B Enrich, O Ludwiczek, M Gabriel, P Obrist, A M Wolf, and H Tilg. Gut 54: 47-487 (2005). (IHC on paraffin sections) 10. Association of Osteoprotegerin With Human Abdominal Aortic Aneurysm Progression. Corey S. Moran, Moira McCann, Mirko Karan, Paul Norman, Natkunam Ketheesan, and Jonathan Golledge. Circulation, Jun 2005; 10. 1161/CIRCULATIONAHA.104.464727. (IHC on paraffin sections) 11. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. Alexander R. Moschen, Arthur Kaser, Sylvia Stadlmann, Gunda Millonig, Susanne Kaser, Petra Mühllechner, Andrzej Habior, Ivo Graziadei, Wolfgang Vogel and Herbert Tilg. Journal of Hepatology 43: 973-983 (2005). (IHC on paraffin sections) 12. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. A.R. Pettit, N.C. Walsh, C. Manning, S.R. Goldring, and E. M. Gravallese. Rheumatology, Feb 2006. (IHC on paraffin sections) |
| Pictures | Western blot analysis for OPG with IMG-103A antibody against Daudi cell lysate. Daudi cell lysate blot was incubated with SM7070P at a dilution of 1 µg/ml and the immunoreactivity was detected by enhanced chemiluminescence.
|
14 Secondary Antibodies
| Catalog No. | Name / Host | Presentation | Reactivity | ||||
|---|---|---|---|---|---|---|---|
| R1253B | Mouse IgG (H&L) | ||||||
| Rabbit | Biotin | 2 mg / US$ 305 | |||||
| R1253F | Mouse IgG (H&L) | ||||||
| Rabbit | FITC | 2 mg / US$ 285 | |||||
| R1253T | Mouse IgG (H&L) | ||||||
| Rabbit | TRITC | 2 mg / US$ 285 | |||||
| R1253TR | Mouse IgG (H&L) | ||||||
| Rabbit | Texas Red | 2 mg / US$ 295 | |||||
| R1253HRP | Mouse IgG (H&L) | ||||||
| Rabbit | HRP | 2 mg / US$ 315 | |||||
| R1253AP | Mouse IgG (H&L) | ||||||
| Rabbit | AP | 1 mg / US$ 325 | |||||
| R1457C2 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy2 | 1 mg / US$ 445 | |||||
| R1457C3 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3 | 1 mg / US$ 445 | |||||
| R1457C35 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3.5 | 1 mg / US$ 445 | |||||
| R1457C5 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5 | 1 mg / US$ 445 | |||||
| R1457C55 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5.5 | 1 mg / US$ 445 | |||||
| R1405R | Mouse IgG (H&L) F(ab')2 Fragment ads. to Bov, Eq, Hu, Rb, Rt, Sh | ||||||
| Goat | PE | 1 ml / US$ 455 | |||||
| R1403R | Mouse IgG (H&L) F(ab')2 Fragment ads. to Hu serum proteins | ||||||
| Rabbit | PE | 1 ml / US$ 455 | |||||
| R1455R | Mouse IgG (H&L) F(ab')2 Fragment multi-species ads. | ||||||
| Donkey | PE | 1 ml / US$ 455 | |||||
Click here to see all secondary antibodies for 'SM7070P Osteoprotegerin'.
